Montelukast Tecnigen

Montelukast, the active ingredient in Montelukast Tecnigen, is a leukotriene receptor antagonist presented as a tablet for oral use. It is used for the prevention and chronic treatment of asthma and for relief of symptoms of allergic rhinitis in adults and children.

GNH USA supplies Montelukast Tecnigen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to control chronic airway inflammation and allergic symptoms. - Asthma: reduces the frequency of bronchospasm and improves overall asthma control. - Allergic rhinitis: alleviates nasal congestion, sneezing, itching and rhinorrhea. - Exercise‑induced bronchoconstriction: prevents airway narrowing triggered by physical activity.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Abdominal pain: occasional discomfort or cramping. - Cough: transient dry cough. - Dyspepsia: indigestion or upset stomach. - Nausea: feeling of queasiness. - Fatigue: mild tiredness.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin reactions requiring immediate medical attention. - Angioedema: swelling of face, lips or tongue. - Hepatic injury: elevated liver enzymes or hepatitis. - Neuropsychiatric events: agitation, depression, or suicidal thoughts. - Anaphylaxis: acute allergic reaction with airway compromise. - Eosinophilic granulomatosis with polyangiitis: rare vasculitic disorder.

Before prescribing Montelukast, clinicians should consider several safety aspects. - Neuropsychiatric monitoring: watch for mood changes, depression or suicidal ideation. - Hepatic function: use caution in patients with liver impairment and monitor liver enzymes. - Acute asthma: not indicated for immediate relief of bronchospasm; provide rescue inhaler. - Elderly patients: assess benefit‑risk ratio due to higher incidence of adverse events. - Hypersensitivity: avoid in individuals with known allergy to montelukast or any tablet excipients. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Montelukast may interact with other medicines that affect its metabolism or pharmacodynamic profile.

Major Interactions (Avoid): - Phenobarbital: strong enzyme inducer that can lower montelukast plasma levels. - Rifampin: induces CYP3A4, potentially reducing therapeutic effect. - Ketoconazole: potent CYP3A4 inhibitor that may increase montelukast exposure.

Moderate Interactions (Monitor Closely): - Warfarin: possible alteration of anticoagulant effect; monitor INR. - Theophylline: may require dose adjustment of theophylline. - Beta‑agonists: additive bronchodilator effect; observe for excessive bronchodilation.